NCT02418819View on ClinicalTrials.gov

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Schizophrenia
Interventions
DRUG

PF-06412562 3mg BID

PF-06412562

DRUG

PF-06412562 9mg BID

PF-06412562

DRUG

PF-06412562 45mg BID

PF-06412562

OTHER

Placebo

Placebo

Trial Locations (6)

20850

Foers Long Term Care Pharmacy LLC, Rockville

20877

CBH Health, LLC, Gaithersburg

21228

Maryland Psychiatric Research Center (MPRC) of the University of Maryland, Baltimore

91007

Arcadia MRI & Imaging Center, Arcadia

91206

California Clinical Trials Medical Group, Glendale

Glendale Adventist Medical Center, Glendale

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02418819 - A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter